With 0.24 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.52 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $42.89 whereas the lowest price it dropped to was $41.56. The 52-week range on MRUS shows that it touched its highest point at $61.61 and its lowest point at $28.41 during that stretch. It currently has a 1-year price target of $87.19. Beta for the stock currently stands at 1.12.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of MRUS was up-trending over the past week, with a rise of 0.43%, but this was down by -5.42% over a month. Three-month performance dropped to -20.29% while six-month performance fell -24.35%. The stock gained 27.28% in the past year, while it has gained 0.43% so far this year. A look at the trailing 12-month EPS for MRUS yields -3.91 with Next year EPS estimates of -3.87. For the next quarter, that number is -0.96. This implies an EPS growth rate of -27.62% for this year and -0.95% for next year. EPS is expected to decline by -13.30% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -18.50%.
Float and Shares Shorts:
At present, 68.43 million MRUS shares are outstanding with a float of 58.58 million shares on hand for trading. On 2024-12-13, short shares totaled 9.78 million, which was 1428.0 higher than short shares on 1731628800. In addition to Dr. Sven Ante Lundberg M.D. as the firm’s CEO, President & Executive Director, Mr. Gregory D. Perry serves as its Chief Financial Officer.
Institutional Ownership:
Through their ownership of 1.06069 of MRUS’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, MRUS reported revenue of $11772000.0 and operating income of -$72232000.0. The EBITDA in the recently reported quarter was -$36647000.0 and diluted EPS was $nan.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for MRUS since 7 analysts follow the stock currently. There are 7 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With MRUS analysts setting a high price target of 109.0 and a low target of 67.0, the average target price over the next 12 months is 86.07143. Based on these targets, MRUS could surge 158.11% to reach the target high and rise by 58.65% to reach the target low. Reaching the average price target will result in a growth of 103.82% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$3.47889 being high and -$4.11401 being low. For MRUS, this leads to a yearly average estimate of -$3.68744. Based on analyst estimates, the high estimate for the next quarter is -$0.58 and the low estimate is -$1.23. The average estimate for the next quarter is thus -$0.94.
